Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 11.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 70,202 shares of the medical research company's stock after selling 9,370 shares during the quarter. Baillie Gifford & Co. owned about 0.14% of Charles River Laboratories International worth $16,596,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $298,877,000. Meritage Group LP purchased a new position in Charles River Laboratories International during the 3rd quarter valued at $173,174,000. Price T Rowe Associates Inc. MD raised its position in Charles River Laboratories International by 35.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company's stock valued at $505,821,000 after purchasing an additional 653,790 shares in the last quarter. Norges Bank bought a new stake in Charles River Laboratories International during the 4th quarter valued at $97,675,000. Finally, Clearbridge Investments LLC raised its position in Charles River Laboratories International by 28.2% during the 1st quarter. Clearbridge Investments LLC now owns 1,368,943 shares of the medical research company's stock valued at $388,739,000 after purchasing an additional 301,159 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Down 0.4 %

Shares of Charles River Laboratories International stock traded down $1.07 during trading on Thursday, reaching $246.42. The company had a trading volume of 318,607 shares, compared to its average volume of 555,644. The company has a market cap of $12.69 billion, a price-to-earnings ratio of 26.76, a price-to-earnings-growth ratio of 2.00 and a beta of 1.40. The firm's fifty day moving average is $252.17 and its 200-day moving average is $219.65. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. Charles River Laboratories International's quarterly revenue was down 7.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.98 earnings per share. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Insider Activity

In other news, VP William D. Barbo sold 4,050 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the completion of the transaction, the vice president now directly owns 22,879 shares in the company, valued at $5,685,431.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares of the company's stock, valued at approximately $626,155.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares of the company's stock, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock worth $3,693,663 over the last three months. Corporate insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. TheStreet upgraded Charles River Laboratories International from a "c+" rating to a "b-" rating in a research note on Friday, March 1st. Evercore ISI raised their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an "outperform" rating in a research report on Thursday, February 15th. Citigroup increased their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the company a "neutral" rating in a research note on Thursday, February 15th. Robert W. Baird raised their price target on Charles River Laboratories International from $252.00 to $268.00 and gave the company an "outperform" rating in a research note on Thursday, February 15th. Finally, UBS Group lifted their target price on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a "buy" rating in a research report on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).